A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma.

Trial Profile

A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Tivozanib (Primary)
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Apr 2012 Results have been published in the Journal of Clinical Oncology according to an AVEO Pharmaceuticals media release.
    • 07 Jun 2011 Final results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2011 Final results were presented at the Annual Meeting of the American Society of Oncology (ASCO-2011).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top